Prelude Therapeutics Inc reports results for the quarter ended in September - Earnings Summary

Prelude Therapeutics Incorporated

18/11/2022 14:01

* Prelude Therapeutics Inc  PRLD.OQ  reported a quarterly
adjusted
loss of 63 cents​​ per share for the quarter ended in September.
The mean expectation of five analysts for the quarter was for a
loss of 64 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Prelude Therapeutics Inc's reported EPS for the quarter
was a
loss of 63 cents​.
    * The mean earnings estimate of analysts had risen by
about 0.3%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Prelude Therapeutics Inc shares had risen by 18.5% this
quarter and lost 37.1% so far this year.
    * The company reported a quarterly loss of $29.96 million.
    * Wall Street's median 12-month price target for Prelude
Therapeutics Inc is $10.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
18 at 02:01 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.64          -0.63          Beat
 Jun. 30 2022      -0.61          -0.58          Beat
 Mar. 31 2022      -0.65          -0.63          Beat
 Dec. 31 2021      -0.68          -0.71          Missed